CMA
TGTX icon

Cedar Mountain Advisors’s TG Therapeutics TGTX Stock Holding History

Cedar Mountain Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$549 Buy
+10
New +$409 ﹤0.01% 1036
2026
Q1 		– Sell
-1
Closed -$30 – 1205
2025
Q4 		$30 Buy
+1
New +$33 ﹤0.01% 734

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Cedar Mountain Advisors's TGTX Position: Q2 2026 in Review

Cedar Mountain Advisors opened a new position in TG Therapeutics (TGTX) in Q2 2026: 10 shares worth $549. The stake represents ﹤0.01% of the portfolio and ranks #1036 among its holdings. This is a return to the name: Cedar Mountain Advisors previously reported a position in TGTX as recently as Q4 2025.

Cedar Mountain Advisors first reported a position in TGTX in Q4 2025 and has held it in 2 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Cedar Mountain Advisors held 10 shares of TG Therapeutics worth $549 as of Q2 2026.
  • TG Therapeutics was a new Cedar Mountain Advisors position in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #1036 holding.
  • Cedar Mountain Advisors first reported a position in TG Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.